✦ LIBER ✦

Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab

✍ Scribed by Michaela Gruber; Karin Fleiss; Edit Porpaczy; Cathrin Skrabs; Alexander W. Hauswirth; Alexander Gaiger; Katrina Vanura; Daniel Heintel; Medhat Shehata; Christine Einberger; Renate Thalhammer; Christa Fonatsch; Ulrich Jäger

Publisher: Springer
Year: 2011
Tongue: English
Weight: 144 KB
Volume: 90
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1260-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of core-binding-factor in acut

Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival

✍ Gautam Borthakur; Hagop Kantarjian; Xuemei Wang; William K. Plunkett Jr; Varsha 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

Fractionated cyclophosphamide, vincristi

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage–colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia

✍ Apostolia M. Tsimberidou; Hagop M. Kantarjian; Jorge Cortes; Deborah A. Thomas; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Therapy for patients with Richter syndrome (RS) or fludarabine‐refractory chronic lymphocytic leukemia (CLL) is unsatisfactory. A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab and granulocyte‐macrophage–colony s